|Day's Range||0.3950 - 0.4269|
|52 Week Range||0.3220 - 1.4600|
|PE Ratio (TTM)||-1.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
RepliCel Life Sciences Inc. (REPCF) (RP.V) is a biotech company looking not to just treat symptoms, but find cures. RepliCel may have the key, not just to rejuvenated skin and functioning tendons, but also a safe way to stop – and perhaps even reverse - hair loss. This week, I held an interview with President & CEO, Lee Buckler, who spoke with great passion of RepliCel's multi-course trajectory.
RepliCel Life Sciences, Inc. (REPCF) (RP.V) is a regenerative medicine company focused on the use of autologous cell therapies for the treatment of cellular deficits. The company is targeting three potentially multi-billion dollar markets: regenerative hair growth, skin aging, and chronic tendinosis.
Cell therapy is hot again! On December 12, 2016, Bayer AG and Versant Ventures joined forces to launch a new stem cell therapy company called BlueRock Therapeutics. BlueRock is focused on breakthrough treatments based on latest stem cell technology.